Is Shree Pacetronix overvalued or undervalued?

Understanding Shree Pacetronix’s Valuation Metrics

At a current price of ₹251.70, Shree Pacetronix trades with a price-to-earnings (PE) ratio of approximately 42.5, which on the surface appears elevated compared to traditional benchmarks. However, this figure must be contextualised within the company’s strong operational performance and growth prospects. The price-to-book value stands at 6.23, reflecting investor confidence in the company’s asset utilisation and future earnings potential.

More telling are the enterprise value multiples: EV to EBIT at 28.82 and EV to EBITDA at 23.84. These ratios, while higher than some peers, are justified by Shree Pacetronix’s impressive return on capital employed (ROCE) of 18.04% and return on equity (ROE) of 14.66%. Such returns indicate efficient capital management and profitability, which often warrant premium valuations.

Notably, the PEG ratio is reported as zero, which may indicate either a lack of consensus on future earnings growth or a data anomaly. Nonetheless, the company’s year-to-date stock return of over 100% significantly outpaces the Sensex’s 8.65% return, underscoring strong market performance and investor enthusiasm.

Peer Comparison Highlights

When compared to its healthcare services peers, Shree Pacetronix’s valuation appears very attractive. For instance, companies like Poly Medicure and Vimta Labs trade at significantly higher PE ratios of 54.6 and 44.21 respectively, with elevated EV to EBITDA multiples and PEG ratios above 1.0, indicating more expensive valuations relative to growth. Meanwhile, Shree Pacetronix’s EV to EBITDA multiple of 23.84 is competitive, especially given its strong profitability metrics.

Other peers such as Raaj Medisafe and BPL are also rated very attractive but have lower PE ratios and different capital structures. Shree Pacetronix’s valuation stands out because it balances a premium multiple with solid returns on capital and equity, suggesting the market may be underestimating its growth trajectory.

Stock Performance and Market Sentiment

Despite a slight pullback in the past week and month, with returns of -4.44% and -2.02% respectively, Shree Pacetronix’s long-term performance is remarkable. Over one year, the stock has delivered a return exceeding 109%, vastly outperforming the Sensex’s 7.31% gain. Over three years, the stock’s return of approximately 101% dwarfs the Sensex’s 36.34%, highlighting sustained investor confidence and operational strength.

The 52-week price range from ₹61.11 to ₹283.15 further illustrates the stock’s volatility but also its capacity for significant appreciation. The current price near ₹251.70 suggests the stock is trading closer to its upper range, yet the valuation grade upgrade to very attractive implies that this price is justified by fundamentals rather than speculative excess.

Conclusion: Undervalued with Strong Growth Potential

In summary, Shree Pacetronix’s valuation metrics, when analysed alongside its robust returns and peer comparisons, indicate that the stock is undervalued rather than overvalued. The recent upgrade in valuation grade to very attractive reflects a market reassessment of the company’s growth prospects and operational efficiency. While the PE ratio is elevated, it is supported by strong ROCE and ROE figures, signalling effective capital deployment and profitability.

Investors should consider Shree Pacetronix as a compelling opportunity within the healthcare services sector, especially given its impressive long-term returns and favourable valuation relative to peers. However, as with all investments, potential buyers should weigh market volatility and sector-specific risks before committing capital.

Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →